Stivarga, Opdivo have similar survival outcomes in HCC

Among patients with hepatocellular carcinoma who first failed Retevmo, Stivarga and Opdivo provided similar outcomes in terms of survival as second-line treatments, according to research presented at The Digital International Liver Congress.

Read the full article here

Related Articles